Enbridge Inc.
—- Market cap
- —
- Debt
- +$105.02B
- Cash
- −$1.09B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2023 · Mkt capMarket cap $45.02B
Decision snapshot: ENB stock price vs RVMD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVMD's multiple
Needs EPS (TTM), RVMD P/E.
Implied fair value · at ENB's multiple
Needs EPS (TTM) is negative, ENB P/E.
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ENB FY 2025 (ended Dec 31, 2025) · RVMD FY 2023 (ended Dec 31, 2023). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 100% equity / 0% debt · EV / Revenue 3744.77x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ENBRIDGE INC. · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.68x
0.11x
Net debt / EBITDA
Leverage against operating earnings
4.14x
3.85x
Cash and equivalents
Liquid reserves on the balance sheet
$1.09B
$1.85B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
KINDER MORGAN, INC.
ENB vs KMI
ONEOK INC /NEW/
ENB vs OKE
TC ENERGY CORP
ENB vs TRP
ENTERPRISE PRODUCTS PARTNERS L.P.
ENB vs EPD
AMGEN INC
ENB vs AMGN
BRISTOL MYERS SQUIBB CO
ENB vs BMY
GILEAD SCIENCES, INC.
ENB vs GILD
INCYTE CORP
ENB vs INCY
VERTEX PHARMACEUTICALS INC / MA
ENB vs VRTX
Moderna, Inc.
ENB vs MRNA
$105.02B
$193.93M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.